This course is FREE with Unlimited CE!

Choose from two Unlimited CE subscription options and get access to 750+ CE and professional development courses.

Get access starting at $49.95/yrLoading..

Goal and Learning Outcomes

The goal of this course is to provide nursing professionals in acute care with guidance on the pharmacological management of acute ischemic stroke with cardiac catheterization, including the etiology, risk factors, and signs and symptoms of ischemic stroke.
After taking this course, you should be able to:
  • Identify the causes and risk factors for ischemic stroke, and the symptoms and diagnostics needed to confirm ischemic stroke.
  • Explain the eligibility and management principles of tissue plasminogen activator (tPA), including patient monitoring and assessment in patients with acute ischemic stroke.

Course Authors

4.9 Average

Course Reviews

28 reviews

Accreditation Information

NURSES

In support of improving patient care, Relias LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Provider approved by the California Board of Registered Nursing, CEP#13791

 

CEBroker

Relias LLC reports to CEBroker for the following boards (Provider # 50-1489): Arkansas State Board Of Nursing, District Of Columbia Board Of Nursing, Florida Board Of Nursing, Georgia Board Of Nursing, New Mexico Board Of Nursing, South Carolina Board Of Nursing and  West Virginia Board Of Examiners For Registered Professional Nurses

 

Please check the licenses/certifications section under my account (after logging in) to make sure you have entered a valid license number. This information is required for correct reporting of your course completions to CE Broker.

 

Disclosures

None of the planners/faculty, unless otherwise noted, for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.